HC Wainwright Issues FY2027 Earnings Estimate for BridgeBio Pharma

Analysts expect the biotech company to post $1.83 per share in earnings for the year.

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

BridgeBio Pharma, Inc. (NASDAQ:BBIO) - HC Wainwright issued their FY2027 earnings per share estimates for BridgeBio Pharma in a report released on Monday, March 9th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of $1.83 per share for the year. HC Wainwright has a "Buy" rating and a $100.00 price objective on the stock. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share.

Why it matters

BridgeBio Pharma is a clinical-stage biopharmaceutical company focused on developing treatments for genetic diseases and cancers. The FY2027 earnings estimate from HC Wainwright provides insight into the company's long-term growth potential and outlook, which is important for investors evaluating the stock.

The details

In the report, HC Wainwright analyst R. Selvaraju expects BridgeBio Pharma to post earnings of $1.83 per share for the fiscal year 2027. This estimate is significantly higher than the current consensus estimate of ($3.67) per share for the company's current full-year earnings. HC Wainwright has a "Buy" rating and a $100.00 price target on BridgeBio Pharma's stock.

  • The report from HC Wainwright was released on Monday, March 9, 2026.

The players

BridgeBio Pharma, Inc.

A clinical-stage biopharmaceutical company headquartered in Palo Alto, California that is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers.

HC Wainwright

An investment banking firm that issued the FY2027 earnings estimate for BridgeBio Pharma.

R. Selvaraju

The HC Wainwright analyst who expects BridgeBio Pharma to post earnings of $1.83 per share in fiscal year 2027.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The FY2027 earnings estimate from HC Wainwright suggests that BridgeBio Pharma's long-term growth prospects remain strong, as the company continues to advance its pipeline of treatments for genetic diseases and cancers. This positive outlook could attract further investor interest in the stock.